Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 25 09:31AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.28 Insider Own10.84% Shs Outstand194.58M Perf Week-4.68%
Market Cap277.42M Forward P/E- EPS next Y-0.27 Insider Trans-0.89% Shs Float186.68M Perf Month-33.75%
Income-51.27M PEG- EPS next Q-0.07 Inst Own18.46% Short Float7.33% Perf Quarter-11.67%
Sales194.75M P/S1.42 EPS this Y0.32% Inst Trans-8.80% Short Ratio2.85 Perf Half Y54.61%
Book/sh-0.16 P/B- EPS next Y1.92% ROA-17.15% Short Interest13.69M Perf Year85.47%
Cash/sh0.20 P/C6.46 EPS next 5Y- ROE-554.87% 52W Range0.65 - 2.48 Perf YTD6.85%
Dividend Est.- P/FCF- EPS past 5Y35.46% ROI-103.44% 52W High-46.57% Beta0.91
Dividend TTM- Quick Ratio1.03 Sales past 5Y5.16% Gross Margin61.47% 52W Low103.85% ATR (14)0.12
Dividend Ex-Date- Current Ratio1.18 EPS Y/Y TTM47.06% Oper. Margin-23.32% RSI (14)36.62 Volatility5.17% 9.92%
Employees167 Debt/Eq- Sales Y/Y TTM-33.42% Profit Margin-26.32% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q106.39% Payout- Rel Volume0.26 Prev Close1.37
Sales Surprise1.45% EPS Surprise100.00% Sales Q/Q2.06% EarningsMar 14 AMC Avg Volume4.81M Price1.33
SMA20-12.89% SMA50-16.17% SMA2000.31% Trades Volume66,360 Change-3.28%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Resumed BTIG Research Buy $4
Aug-28-23Upgrade H.C. Wainwright Neutral → Buy $3.75
May-31-23Upgrade Piper Sandler Neutral → Overweight $2 → $4
Mar-31-22Downgrade Piper Sandler Overweight → Neutral $8 → $2
Mar-31-22Downgrade Needham Buy → Hold
Mar-31-22Downgrade Mizuho Buy → Neutral $6 → $2
Mar-31-22Downgrade H.C. Wainwright Buy → Neutral $10 → $2
Mar-08-21Initiated Cantor Fitzgerald Overweight $8
Jan-29-21Downgrade JP Morgan Neutral → Underweight
Nov-14-19Reiterated Needham Buy $18 → $15
Apr-02-24 04:05PM
Mar-28-24 11:50AM
Mar-27-24 08:26PM
Mar-26-24 01:12PM
09:53PM Loading…
Mar-14-24 09:53PM
Mar-11-24 05:05PM
Mar-01-24 04:05PM
Feb-02-24 04:05PM
Jan-30-24 08:00AM
Jan-09-24 08:30AM
Jan-02-24 04:30PM
08:00AM Loading…
Dec-20-23 08:00AM
Dec-01-23 04:05PM
Nov-20-23 08:00AM
Nov-09-23 11:32AM
Nov-08-23 10:05PM
Nov-02-23 04:30PM
Nov-01-23 04:05PM
Oct-31-23 08:00AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
Oct-18-23 08:00AM
Oct-03-23 04:05PM
08:00AM Loading…
Sep-28-23 08:00AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Sep-05-23 04:05PM
Aug-31-23 06:15AM
Aug-28-23 12:18PM
Aug-25-23 10:25PM
Aug-24-23 08:00AM
Aug-23-23 04:35PM
Aug-17-23 04:05PM
Aug-10-23 05:40PM
Aug-01-23 04:30PM
Jul-26-23 09:40AM
Jul-19-23 07:45AM
Jul-18-23 07:45AM
Jul-06-23 06:07AM
Jul-04-23 07:34AM
Jun-29-23 08:00AM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-20-23 08:00AM
Jun-19-23 09:40AM
Jun-13-23 07:00AM
Jun-08-23 01:20PM
Jun-02-23 12:00PM
Jun-01-23 04:05PM
May-30-23 07:30AM
May-25-23 08:00AM
May-23-23 11:27AM
May-22-23 05:15PM
May-10-23 09:40AM
May-09-23 02:12AM
May-08-23 08:45AM
May-04-23 10:00AM
May-01-23 10:01AM
Apr-25-23 02:30PM
Apr-19-23 01:07PM
Apr-14-23 08:30AM
Apr-11-23 11:15AM
Apr-07-23 08:30AM
Apr-04-23 04:05PM
Apr-03-23 08:30AM
Mar-30-23 08:30AM
Mar-24-23 08:30AM
Mar-13-23 02:51AM
Mar-09-23 10:42PM
Mar-02-23 08:30AM
Feb-23-23 04:05PM
Feb-21-23 06:30AM
Feb-01-23 04:05PM
Jan-03-23 04:05PM
Dec-22-22 08:45AM
Dec-02-22 04:05PM
Nov-22-22 04:05PM
Nov-09-22 06:10AM
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Butler John P.CEO and PresidentFeb 29 '24Sale1.5846,57073,5812,044,580Mar 01 05:47 PM
Dahan MichelSVP, Chief Operating OfficerFeb 29 '24Sale1.588,66113,684706,932Mar 01 05:49 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 29 '24Sale1.587,16911,327695,840Mar 01 05:46 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 29 '24Sale1.585,9749,439663,259Mar 01 05:48 PM
Butler John P.CEO and PresidentFeb 27 '24Sale1.5237,73357,3542,091,150Feb 29 06:00 PM
Dahan MichelSVP, Chief Operating OfficerFeb 27 '24Sale1.5210,74416,331715,593Feb 29 06:02 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 27 '24Sale1.528,36712,718703,009Feb 29 06:01 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 27 '24Sale1.527,41111,265669,233Feb 29 06:03 PM
Butler John P.CEO and PresidentFeb 01 '24Sale1.6846,48978,1022,128,883Feb 02 04:10 PM
Burke Steven KeithSVP, Chief Medical OfficerFeb 01 '24Sale1.6824,31140,842711,376Feb 02 04:10 PM
Dahan MichelSVP, Chief Operating OfficerMay 25 '23Sale1.2295,478116,760574,037May 25 09:01 PM
Hadas Nicole R.SVP, Chief Legal OfficerMay 25 '23Sale1.2263,18677,270524,344May 25 09:01 PM
Burke Steven KeithSVP, Chief Medical OfficerMay 16 '23Sale1.0763,56767,890530,487May 18 06:20 PM
Spellman David ASVP, CFO and TreasurerMay 16 '23Sale1.0763,56767,890446,483May 18 06:19 PM